These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21785677)

  • 21. Fingolimod for relapsing-remitting multiple sclerosis.
    La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered Immune Phenotypes and
    Devi-Marulkar P; Moraes-Cabe C; Campagne P; Corre B; Meghraoui-Kheddar A; Bondet V; Llibre A; Duffy D; Maillart E; Papeix C; Pellegrini S; Michel F
    Front Immunol; 2021; 12():628375. PubMed ID: 34113337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Giovannoni G; Cohen JA; Coles AJ; Hartung HP; Havrdova E; Selmaj KW; Margolin DH; Lake SL; Kaup SM; Panzara MA; Compston DA;
    Neurology; 2016 Nov; 87(19):1985-1992. PubMed ID: 27733571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
    Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies.
    Einarson TR; Bereza BG; Machado M
    Curr Med Res Opin; 2017 Mar; 33(3):579-593. PubMed ID: 28027680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Tolley K; Hutchinson M; You X; Wang P; Sperling B; Taneja A; Siddiqui MK; Kinter E
    PLoS One; 2015; 10(6):e0127960. PubMed ID: 26039748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran.
    Pakdaman H; Amini Harandi A; Gharagozli K; Abbasi M; Tabassi A; Ashrafi F; Ghaffarpor M; Sharifi S; Delavar Kasmae H; Assarzadegan F; Arabahmadi M; Behnam B
    Int J Neurosci; 2017 Jun; 127(6):501-507. PubMed ID: 27279451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saliva soluble HLA as a potential marker of response to interferon-beta 1a in multiple sclerosis: a preliminary study.
    Minagar A; Adamashvili I; Kelley RE; Gonzalez-Toledo E; McLarty J; Smith SJ
    J Neuroinflammation; 2007 Jul; 4():16. PubMed ID: 17601341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
    J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized trial of daily high-dose vitamin D
    Hupperts R; Smolders J; Vieth R; Holmøy T; Marhardt K; Schluep M; Killestein J; Barkhof F; Beelke M; Grimaldi LME;
    Neurology; 2019 Nov; 93(20):e1906-e1916. PubMed ID: 31594857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis.
    Rieckmann P; Heidenreich F; Sailer M; Zettl UK; Zessack N; Hartung HP; Gold R
    Ther Adv Neurol Disord; 2012 Jan; 5(1):3-12. PubMed ID: 22276072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Benedict RH; Cohan S; Lynch SG; Riester K; Wang P; Castro-Borrero W; Elkins J; Sabatella G
    Mult Scler; 2018 May; 24(6):795-804. PubMed ID: 28485186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.